Association of cardiac biomarkers with long-term cardiovascular events in a community cohort

References

• AbouEzzeddine OF, McKie PM, Scott CG, Rodeheffer RJ, Chen HH, Michael Felker G, Jaffe AS, Burnett JC, Redfield MM. 2016. Biomarker-based risk prediction in the community. Eur J Heart Fail. 18 (11):1342–1350. doi: 10.1002/ejhf.663
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Chambless LE, Ballantyne CM, Astor B, Bertoni AG, Chang PP, Folsom AR, He M, Hoogeveen RC, Ni H, et al. 2012. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) study. Circ Heart Fail. 5 (4):422–429. doi: 10.1161/CIRCHEARTFAILURE.111.964841
   PubMed Web of Science ®Google Scholar
• Albeituni S, Stiban J. 2019. Roles of ceramides and other sphingolipids in immune cell function and inflammation. The role of bioactive lipids in cancer, inflammation and related diseases. New York (NY): Springer International Publishing; p. 169–191.
   Google Scholar
• Beatty AL, Ku IA, Christenson RH, DeFilippi CR, Schiller NB, Whooley MA. 2013. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med. 173 (9):763–769. doi: 10.1001/jamainternmed.2013.116
   PubMed Web of Science ®Google Scholar
• Cao H, Qadri SM, Lang E, Pelzl L, Umbach AT, Leiss V, Birnbaumer L, Nürnberg B, Pieske B, Voelkl J, et al. 2018. Heterotrimeric G-protein subunit Gαi2 contributes to agonist-sensitive apoptosis and degranulation in murine platelets. Physiol Rep. 6 (17):e13841. doi: 10.14814/phy2.13841
   PubMedGoogle Scholar
• Chia YC, Lim HM, Ching SM. 2014. Validation of the pooled cohort risk score in an Asian population – a retrospective cohort study. BMC Cardiovasc Disord. 14 (1):163. doi: 10.1186/1471-2261-14-163
   PubMedGoogle Scholar
• Clerico A. 2002. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? J Clin Chem Lab Med. 40 (8):752–760. doi: 10.1515/CCLM.2002.129
   Google Scholar
• Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. 2004. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the ElecsysTM 1010 and 2010 analysers. Eur J Heart Fail. 6 (3):365–368. doi: 10.1016/j.ejheart.2004.01.011
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC. 2006. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 47 (2):345–353. doi: 10.1016/j.jacc.2005.09.025
   PubMed Web of Science ®Google Scholar
• Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray T. 2019. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 17 (1):109. doi: 10.1186/s12916-019-1340-7
   PubMedGoogle Scholar
• Desai YB, Mishra RK, Fang Q, Whooley MA, Schiller NB. 2020. Association of longitudinal change in high-sensitivity troponin with all-cause mortality in coronary artery disease: the heart and soul study. Cardiology. 145 (2):63–70. doi: 10.1159/000503954
   PubMed Web of Science ®Google Scholar
• Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. 2015. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 131 (21):1851–1860. doi: 10.1161/CIRCULATIONAHA.114.014522
   PubMed Web of Science ®Google Scholar
• Farnsworth CW, Bailey AL, Jaffe AS, Scott MG. 2018. Diagnostic concordance between NT-proBNP and BNP for suspected heart failure. Clin Biochem. 59:50–55. doi: 10.1016/j.clinbiochem.2018.07.002
   PubMed Web of Science ®Google Scholar
• Hall C. 2005. NT-ProBNP: the mechanism behind the marker. J Card Fail. 11(5):S81–S83. doi: 10.1016/j.cardfail.2005.04.019
   PubMed Web of Science ®Google Scholar
• Harada M, Saito Y, Kuwahara K, Ogawa E, Ishikawa M, Nakagawa O, Miyamoto Y, Kamitani S, Hamanaka I, Kajiyama N, et al. 1998. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol. 31(1):S357–S359. doi: 10.1097/00005344-199800001-00100
   PubMedGoogle Scholar
• Harmon DM, AbouEzzeddine OF, McKie PM, Scott CG, Saenger AK, Jaffe AS. 2021. Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. Biomarkers. 26(7):639–646. doi: 10.1080/1354750X.2021.1956590
   PubMed Web of Science ®Google Scholar
• Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, Salomaa V, Laaksonen R. 2016. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 36(12):2424–2430. doi: 10.1161/ATVBAHA.116.307497
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JONIJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022. AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Card Fail. 28(5):810–830. doi: 10.1016/j.cardfail.2022.02.009
   PubMed Web of Science ®Google Scholar
• Hilvo M, Simolin H, Metso J, Ruuth M, Öörni K, Jauhiainen M, Laaksonen R, Baruch A. 2018. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions. Atherosclerosis. 269:159–165. doi: 10.1016/j.atherosclerosis.2018.01.004
   PubMed Web of Science ®Google Scholar
• Hystad ME, Geiran OR, Attramadal H, Spurkland A, Vege Å, Simonsen S, Hall C. 2001. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand. 171(4):395–403. doi: 10.1046/j.1365-201X.2001.00805.x
   PubMedGoogle Scholar
• James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, et al. 2003. N-terminal pro–brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation. 108(3):275–281. doi: 10.1161/01.CIR.0000079170.10579.DC
   PubMed Web of Science ®Google Scholar
• Jeffreys H. 1946. An invariant form for the prior probability in estimation problems. Proc R Soc Lond A Math Phys Sci. 186(1007):453–461. doi: 10.1098/rspa.1946.0056
   PubMed Web of Science ®Google Scholar
• Kauhanen D, Sysi-Aho M, Koistinen KM, Laaksonen R, Sinisalo J, Ekroos K. 2016. Development and validation of a high-throughput LC–MS/MS assay for routine measurement of molecular ceramides. Anal Bioanal Chem. 408(13):3475–3483. doi: 10.1007/s00216-016-9425-z
   PubMed Web of Science ®Google Scholar
• Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen H-U, Zeiher AM. 2013. Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol. 102(4):259–268. doi: 10.1007/s00392-012-0530-5
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, and Collins, R. 2007. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet. 370(9635):372. doi: 10.1016/S0140-6736(07)61778-4
   PubMedGoogle Scholar
• Li W, Yang X, Xing S, Bian F, Yao W, Bai X, Zheng T, Wu G, Jin S. 2014. Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall. Oxid Med Cell Longev. 2014:823071–11. doi: 10.1155/2014/823071
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2020. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC. 2010. The prognostic value of N-terminal pro–B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 55(19):2140–2147. doi: 10.1016/j.jacc.2010.01.031
   PubMed Web of Science ®Google Scholar
• McKie PM, Heublein DM, Scott CG, Gantzer M. l, Mehta RA, Rodeheffer RJ, Redfield MM, Burnett JC, Jr., Jaffe AS. 2013. Defining high-sensitivity cardiac troponin concentrations in the community. Clin Chem. 59(7):1099–1107. doi: 10.1373/clinchem.2012.198614
   PubMed Web of Science ®Google Scholar
• Meeusen JW, Donato LJ, Bryant SC, Baudhuin LM, Berger PB, Jaffe AS. 2018. Plasma ceramides. Arterioscler Thromb Vasc Biol. 38(8):1933–1939. doi: 10.1161/ATVBAHA.118.311199
   PubMed Web of Science ®Google Scholar
• Mishra RK, Beatty AL, Jaganath R, Regan M, Wu AHB, Whooley MA. 2014. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study. J Am Heart Assoc. 3(4):e000907. doi: 10.1161/JAHA.114.000907
   PubMed Web of Science ®Google Scholar
• Morris PB, Ballantyne CM, Birtcher KK, Dunn SP, Urbina EM. 2014. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 64(2):196–206. doi: 10.1016/j.jacc.2014.05.015
   PubMed Web of Science ®Google Scholar
• Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal S, Boerwinkle E, Hoogeveen RC, Aguilar D, Astor BC, et al. 2013. Troponin T and N-terminal pro–B-type natriuretic peptide: a biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. Clin Chem. 59(12):1802–1810. doi: 10.1373/clinchem.2013.203638
   PubMed Web of Science ®Google Scholar
• Ndumele CE, Matsushita K, Sang Y, Lazo M, Agarwal SK, Nambi V, Deswal A, Blumenthal RS, Ballantyne CM, Coresh J, et al. 2016. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 133(7):631–638. doi: 10.1161/CIRCULATIONAHA.115.017298
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB, D’Agostino RB, Vasan RS. 2008. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 27(2):157–172. doi: 10.1002/sim.2929
   PubMed Web of Science ®Google Scholar
• Predescu S, Knezevic I, Bardita C, Neamu RF, Brovcovych V, Predescu D. 2013. Platelet activating factor-induced ceramide micro-domains drive endothelial NOS activation and contribute to barrier dysfunction. PLoS One. 8(9):e75846. doi: 10.1371/journal.pone.0075846
   PubMed Web of Science ®Google Scholar
• Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. 2016. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 67(18):2118–2130. doi: 10.1016/j.jacc.2016.02.055
   PubMed Web of Science ®Google Scholar
• Sawada Y, Suda M, Yokoyama H, Kanda T, Sakamaki T, Tanaka S, Nagai R, Abe S, Takeuchi T. 1997. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem. 272(33):20545–20554. doi: 10.1074/jbc.272.33.20545
   PubMed Web of Science ®Google Scholar
• Schafer JL. 1997. Analysis of incomplete multivariate data. Boca Raton (FL): CRC Press.
   Google Scholar
• Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. 1996. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest. 98(6):1455–1464. doi: 10.1172/JCI118934
   PubMed Web of Science ®Google Scholar
• Sigruener A, Kleber ME, Heimerl S, Liebisch G, Schmitz G, Maerz W. 2014. Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. PLoS One. 9(1):e85724. doi: 10.1371/journal.pone.0085724
   Web of Science ®Google Scholar
• Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. 2019. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 4(12):1287–1295. doi: 10.1001/jamacardio.2019.3780
   PubMed Web of Science ®Google Scholar
• Sudoh T, Minamino N, Kangawa K, Matsuo H. 1990. C-Type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 168 (2):863–870. doi: 10.1016/0006-291x(90)92401-k.
   PubMed Web of Science ®Google Scholar
• Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, Gouni-Berthold I, Berthold HK, Kleber ME, Laaksonen R, et al. 2014. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 99 (1):E45–E52. doi: 10.1210/jc.2013-2559
   PubMed Web of Science ®Google Scholar
• Vasile VC, Meeusen JW, Medina Inojosa JR, Donato LJ, Scott CG, Hyun MS, Vinciguerra M, Rodeheffer RR, Lopez-Jimenez F, Jaffe AS. 2021. Ceramide scores predict cardiovascular risk in the community. Arterioscler Thromb Vasc Biol. 41(4):1558–1569. doi: 10.1161/ATVBAHA.120.315530
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2020. The top 10 causes of death [online]. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
   Google Scholar
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF, Vasan RS. 2004. Impact of obesity on plasma natriuretic peptide levels. Circulation. 109 (5):594–600. doi: 10.1161/01.CIR.0000112582.16683.EA
   PubMed Web of Science ®Google Scholar
• Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, Razquin C, Zheng Y, Ruiz-Canela M, Guasch-Ferré M, et al. 2017. Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevención con Dieta Mediterránea). Circulation. 135 (21):2028–2040. doi: 10.1161/CIRCULATIONAHA.116.024261
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. 1998. Prediction of coronary heart disease using risk factor categories. Circulation. 97(18):1837–1847. doi: 10.1161/01.cir.97.18.1837
   PubMed Web of Science ®Google Scholar